| Methods |
Multicentre RCT
2 arms
Quality score: B |
| Participants |
n = 77
Metastatic disease: 46%
ECOG 2‐3: 88% |
| Interventions |
FA: 5‐FU 270 to 300 mg/m² CI d 1‐ 5; adriamycin 25 mg/m² d 5, repeated at d 22
versus
FAP: 5‐FU 270 to 300 mg/m² CI d 1‐ 5; adriamycin 25 mg/m² d 5; cisplatin 70 mg/m² d 1, repeated at d 22 |
| Outcomes |
Median survival
Response rates |
| Notes |
Translated from Japanese |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not stated |
| Allocation concealment (selection bias) |
Low risk |
Sequential opaque envelopes |
| Incomplete outcome data (attrition bias)
efficacy |
Low risk |
All evaluable pts analysed |
| Incomplete outcome data (attrition bias)
safety |
Low risk |
All evaluable pts analysed |
| Selective reporting (reporting bias) |
Low risk |
Report includes all expected outcomes |
| Other bias |
Unclear risk |
N/A |
| Blinded review of CT/MRI‐scans? |
High risk |
Evaluated during group meetings |
